EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide

Toshiki Terao, Takafumi Tsushima, Ami Fukumoto, Ayumi Kuzume, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Kosei Matsue

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Here, we describe the case of a male patient with Epstein-Barr virus post-transplantation lymphoproliferative disorder (EBV-PTLD), which developed 18 months after a haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and the administration of post-transplant cyclophosphamide (PTCy). Of note, no anti-thymoglobulin was used in the entire clinical course. Prior to the onset of EBV-PTLD, the patient had pulmonary chronic graft-versus-host disease and was treated with prednisolone and tacrolimus. After stopping immunosuppressive therapy, he was diagnosed with EBV-positive infectious mononucleosis PTLD, and EBV-associated hemophagocytic syndrome; therefore, dexamethasone and rituximab monotherapies were administered. After four courses of rituximab, EBV-DNA was no longer detected in the peripheral blood, and the patient’s laboratory data improved. Overall, this study highlights the need to predict the risk factors associated with the development of EBV-PTLD in transplanted patients after haplo-HSCT with PTCy.

Original languageEnglish
Pages (from-to)136-140
Number of pages5
JournalInternational journal of hematology
Issue number1
Publication statusPublished - Jul 2021
Externally publishedYes


  • Chronic graft-versus-host disease
  • Epstein-Barr virus
  • Haploidentical stem-cell transplantation
  • Post-transplant cyclophosphamide
  • Post-transplantation lymphoproliferative disorder

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide'. Together they form a unique fingerprint.

Cite this